TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company’s initial funding in 2018.
TAE Technologies is pleased to announce the re-appointment of Marco Arese to its Board of Directors. Arese brings a wealth of entrepreneurial experience activating global capital, scaling international business, and cultivating renewable energy opportunities, all of which he will leverage on behalf of the company as it continues commercialization of its transformational technologies.
TAE Technologies’ modeling group has won a 2018 US Department of Energy INCITE (Innovative and Novel Computational Impact on Theory and Experiment) award on the Argonne Leadership Computing Facility’s Theta supercomputer. The award is for 31MCH (million core hours), which is equivalent to 100MCH on ALCF’s Blue Gene supercomputer, Mira, and will be used to accelerate our research in creating clean fusion energy.
TAE Technologies recently welcomed the Department of Energy and Secretary Rick Perry for a tour of our National Laboratory-scale platform, Norman. “It was an honor to host the Secretary and share with him our enthusiasm for the opportunities our fusion pathway can provide,” said CEO Michl Binderbauer.
TAE Technologies is proud to announce new executive appointments to lead the next phase of the company’s growth: Michl Binderbauer has been named Chief Executive Officer, assuming leadership from retiring CEO Dr. Steven Specker. Former GE Chairman and CEO Jeffrey R. Immelt joins the company’s Board of Directors.